Literature DB >> 7870992

Trial 2 in the elevated plus-maze: a different form of fear?

S E File1, H Zangrossi, M Viana, F G Graeff.   

Abstract

A factor analysis of the scores from rats given two trials in the elevated plus-maze showed that four independent factors emerged. Measures of anxiolytic activity on trial 1 (number of open arm entries and time spent on open arms) loaded on factor 1, measures of anxiolytic activity on trial 2 loaded on factor 2, the measure of general activity (number of closed arm entries) on both trials loaded on factor 3, and a measure of decision time (time spent in central square) for both trials loaded on factor 4. The independence of trials 1 and 2 anxiety measures raises the possibility that the state of anxiety/fear on the second trial in the plus-maze is qualitatively different from that on trial 1. This difference is reflected in the loss of anxiolytic action of diazepam (2 mg/kg) on trial 2. However, this occurs only when the trials are short (5 min); when they are longer (10 min) diazepam retains anxiolytic efficacy. It is concluded that during a brief (5 min) trial in the plus-maze rats acquire a specific phobic anxiety, which is relatively resistant to benzodiazepines. With a longer exposure to the plus-maze this form of fear extinguishes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870992     DOI: 10.1007/bf02253541

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  Characterisation of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze.

Authors:  S E File; P S Mabbutt; P K Hitchcott
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Early life protein malnutrition changes exploration of the elevated plus-maze and reactivity to anxiolytics.

Authors:  S S Almeida; L M de Oliveira; F G Graeff
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  The use of a plus-maze to measure anxiety in the mouse.

Authors:  R G Lister
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Modification of chlordiazepoxide's behavioural and neurochemical effects by handling and plus-maze experience.

Authors:  S E File; N Andrews; P Y Wu; A Zharkovsky; H Zangrossi
Journal:  Eur J Pharmacol       Date:  1992-07-21       Impact factor: 4.432

5.  Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience.

Authors:  R J Rodgers; C Lee; J K Shepherd
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors.

Authors:  M A Critchley; S L Handley
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze.

Authors:  S E File
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

  7 in total
  30 in total

1.  On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA.

Authors:  A Richard Green; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2002-08       Impact factor: 4.530

2.  Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats.

Authors:  Leandro J Bertoglio; Antonio P Carobrez
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

3.  Free versus forced exposure to an elevated plus-maze: evidence for new behavioral interpretations during test and retest.

Authors:  Vincent Roy; Pierre Chapillon; Mustapha Jeljeli; Jean Caston; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2008-11-08       Impact factor: 4.530

4.  Effects of Various Cleaning Agents on the Performance of Mice in Behavioral Assays of Anxiety.

Authors:  John D Hershey; Janace J Gifford; Lauren J Zizza; Darya A Pavlenko; George C Wagner; Shoreh Miller
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-06-27       Impact factor: 1.232

Review 5.  Contextual conditioning in rats as an animal model for generalized anxiety disorder.

Authors:  Laura Luyten; Debora Vansteenwegen; Kris van Kuyck; Loes Gabriëls; Bart Nuttin
Journal:  Cogn Affect Behav Neurosci       Date:  2011-06       Impact factor: 3.282

6.  A five minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus.

Authors:  L E Gonzalez; S E File
Journal:  J Neurosci       Date:  1997-02-15       Impact factor: 6.167

7.  Long-term effect of in vitro culture of mouse embryos with serum on mRNA expression of imprinting genes, development, and behavior.

Authors:  Raúl Fernández-Gonzalez; Pedro Moreira; Ainhoa Bilbao; Adela Jiménez; Miriam Pérez-Crespo; Miguel Angel Ramírez; Fernando Rodríguez De Fonseca; Belén Pintado; Alfonso Gutiérrez-Adán
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

8.  Heightened drug-seeking motivation following extended daily access to self-administered cocaine.

Authors:  Osnat Ben-Shahar; Eric J Posthumus; Stephanie A Waldroup; Aaron Ettenberg
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-01-11       Impact factor: 5.067

9.  Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats.

Authors:  M D S Lapiz-Bluhm; C O Bondi; J Doyen; G A Rodriguez; T Bédard-Arana; D A Morilak
Journal:  J Neuroendocrinol       Date:  2008-07-30       Impact factor: 3.627

10.  Individual differences in the sensitivity to serotonergic drugs: a pharmacobehavioural approach using rats selected on the basis of their response to novelty.

Authors:  Michel M M Verheij; Jesse V Veenvliet; Tom Groot Kormelink; Maaike Steenhof; Alexander R Cools
Journal:  Psychopharmacology (Berl)       Date:  2009-05-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.